Acutaas Chemicals Limited (NSE:ACUTAAS)

Market Cap	182.40B +102.1%
Revenue (ttm)	12.15B +31.6%
Net Income	2.87B +136.4%
EPS	34.76 +159.1%
Shares Out	81.87M
PE Ratio	64.10
Forward PE	49.98
Dividend	1.50 (0.07%)
Ex-Dividend Date	Sep 18, 2025

Volume	187,263
Average Volume	367,767
Open	2,229.90
Previous Close	2,227.90
Day's Range	2,196.50 - 2,259.60
52-Week Range	976.55 - 2,297.30
Beta	0.07
RSI	62.05
Earnings Date	May 30, 2026

About Acutaas Chemicals

Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 2004
• Employees: 879
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACUTAAS

Financial Performance

In fiscal year 2025, Acutaas Chemicals's revenue was 10.07 billion, an increase of 40.34% compared to the previous year's 7.17 billion. Earnings were 1.59 billion, an increase of 271.06%.